BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Taxotere (Docetaxel) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Taxotere (Docetaxel)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03951831-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03951831)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: REGN2
 810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive 
 Prostate Cancer\nEstimated primary completion: November 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03951831
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118333-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06118333)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: A Study Comparing BL-B0
 1D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or 
 Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)\nEstimated primary comple
 tion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06118333
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05094336-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05094336)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: A Study of Anvumetost
 at in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)\nE
 stimated primary completion: 30 November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05094336
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749886-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06749886)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: An Exploratory Study of Tislelizumab in Combination with Chemotherap
 y in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCL
 C in the Second-line Setting\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06749886
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02889666-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT02889666)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02889666
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03258320-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT03258320)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Prostate Cancer.\nStudy: A R
 andomised Trial of Cabazitaxel\, Docetaxel\, Mitoxantrone or Satraplatin (
 CDMS) Plus Surgery for Prostate Cancer Patients\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ocetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03258320
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03903835-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT03903835)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: ProBio: A Biomarker Driven Study in Patients Wi
 th Metastatic Prostate Cancer\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03903835
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05054439-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05054439)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: A Clinical Study of SI-B001 in Combination With Paclitaxe
 l/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC\nEstimated 
 primary completion: December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05054439
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645380-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05645380)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Neoadjuvant TIL- and Re
 sponse-Adapted Chemoimmunotherapy for TNBC\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doceta
 xel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05645380
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05925491-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05925491)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Pembrolizumab in Locall
 y Advanced Sinonasal Carcinoma\nEstimated primary completion: December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05925491
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382129-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06382129)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresecta
 ble Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Canc
 er(PANKU-Lung02)\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06382129
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568094-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06568094)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Prostate Cancer.\nStudy: A S
 tudy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With 
 Advanced Prostate Cancer\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06568094
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: AK129 Combination Therapy for Advanced Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06943820
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05634369-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05634369)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: A Multi-Institution S
 tudy of TGFβ Imprinted\, Ex Vivo Expanded Universal Donor NK Cell Infusio
 ns as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel
  in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue\nE
 stimated primary completion: 1 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05634369
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480110-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06480110)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Ebastine in Combination With Docetaxel as a T
 reatment for Castration-resistant Metastatic Prostate Cancer\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06480110
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT04185883)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: Sotorasib Activity in S
 ubjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 10
 1)\nEstimated primary completion: 17 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06783647)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Clinical Trial of LBL-024 Combination Drug in Patients With Advanc
 ed Solid Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 83647
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525350-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06525350)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of the Combination of Gl
 umetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment
  of MET-overexpressed Non-small Cell Lung Cancer\nEstimated primary comple
 tion: 25 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06525350
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381829-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT07381829)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: A Phase Ib Clinical Stu
 dy on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung 
 Cancer\nEstimated primary completion: 30 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07381829
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combinat
 ion of Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04140526
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04329065-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04329065)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Concurrent WOKVAC Vacci
 nation\, Chemotherapy\, and HER2-Targeted Monoclonal Antibody Therapy Befo
 re Surgery for the Treatment of Patients With Breast Cancer\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04329065
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04633252-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04633252)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Prostate Cancer.\nStudy: A P
 hase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With 
 Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration 
 Resistant Prostate Cancer\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04633252
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024734-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05024734)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Guiding Instillation in
  Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Deriv
 ed Organoids\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05024734
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05813015-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT05813015)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: Study of Comparing of W
 ith and Without Sequential Therapy of S-1\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doce
 taxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05813015
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867420-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05867420)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: A Study of ASKG915 in
  Patients With Selected Advanced Solid Tumors.\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05867420
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978648-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05978648)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Trilaciclib in Patients
  With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherap
 y\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05978648
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330050-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07330050)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant 
 Advanced NSCLC\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07330050
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06741644-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06741644)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: A Phase I/II Study of
  CS2009 in Participants With Advanced Solid Tumors\nEstimated primary comp
 letion: January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06741644
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879717-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06879717)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Roginolisib (IOA-244) in Combination With Dostarlimab W
 ith or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) 
 Patients\nEstimated primary completion: January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06879717
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04015622-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04015622)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: PROstate Cancer TReatment Optimization Via Anal
 ysis of Circulating Tumour DNA\nEstimated primary completion: 31 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04015622
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257575-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07257575)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Rand
 omized Controlled Study of Serplulimab Combined With Chemotherapy for Loca
 lly Advanced Gastric Adenocarcinoma\nEstimated primary completion: 31 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07257
 575
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076760-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05076760)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: MEM-288 Oncolytic Virus Alone and in Combination With Standard of Ca
 re Therapy in Advanced Solid Tumors\nEstimated primary completion: Februar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0507676
 0
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228326-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06228326)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor 
 Malignancies Affecting the Lungs\nEstimated primary completion: February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06228326
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03456843-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03456843)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Thera
 peutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Dia
 gnosed Metastatic Prostate Cancer\nEstimated primary completion: March 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03456843
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632951-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06632951)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Study to Evaluate Adver
 se Events and Change in Disease Activity When Intravenously (IV) Infused L
 ivmoniplimab is Used in Combination With IV Infused Budigalimab in Adult P
 articipants With Urothelial Carcinoma (UC)\nEstimated primary completion: 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066
 32951
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02817633-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT02817633)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: A Study of TSR-022 in P
 articipants With Advanced Solid Tumors (AMBER)\nEstimated primary completi
 on: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT02817633
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06684158-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06684158)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Mecapegfilgrastim Combi
 ned With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable
  GC/GEJC\nEstimated primary completion: 1 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06684158
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04540692-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT04540692)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Evaluation of Sequencing of Anthracyclines and Taxanes for L
 ocally Advanced HER2-negative Breast Cancer\nEstimated primary completion:
  April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxe
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 540692
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136988-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06136988)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: A Study of Docetaxel 
 for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and 
 Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squ
 amous Carcinoma.\nEstimated primary completion: April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06136988
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06409390)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for Br
 east Cancer\nEstimated primary completion: April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03574571-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT03574571)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: A Stu
 dy to Test Radium-223 With Docetaxel in Patients With Prostate Cancer\nEst
 imated primary completion: 1 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03574571
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06028737-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06028737)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Gastric Cancer.\nStudy: Tota
 l Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesop
 hageal Junction Cancer\nEstimated primary completion: 25 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06028737
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06102395)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Evaluating the Efficacy and Safety of Pembrolizumab Plus 
 Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) 
 HNSCC\nEstimated primary completion: 30 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06102395
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947291-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06947291)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Safety
  and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin
 -bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction
  Adenocarcinoma and Other Solid Tumors\nEstimated primary completion: 30 A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0694
 7291
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999994-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05999994)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Master Protocol (LY90
 0023) That Includes Several Clinical Trials of Drugs for Children and Youn
 g Adults With Cancer\nEstimated primary completion: May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05999994
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421298-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06421298)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Prospective\, Single-arm\, Phase II Clinical Trial to Evaluate the
  Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemother
 apy in Patients With Advanced or Metastatic Driver Gene-negative Non-small
  Cell Lung Cancer After Failure of First-line Immunotherapy.\nEstimated pr
 imary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06421298
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03421288-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03421288)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Study 
 of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Imm
 une Responsiveness\nEstimated primary completion: 31 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03421288
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03598595-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT03598595)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: Gemcitabine\, Docetax
 el\, and Hydroxychloroquine in Treating Participants With Recurrent or Ref
 ractory Osteosarcoma\nEstimated primary completion: 31 May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03598595
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733689-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05733689)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: Response Adapted Neoadj
 uvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)\nEstimated prima
 ry completion: June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05733689
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070440-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07070440)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: DZD6008 Combination Therapy in Patients With Locally Advanced or M
 etastatic NSCLC With EGFR Mutation (TIAN-SHAN7)\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docet
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07070440
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04812366-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04812366)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Genom
 ic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized P
 rostate Cancer\nEstimated primary completion: 1 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04812366
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722523-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT04722523)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: A Study of Cemiplimab With Chemotherapy and Immunotherapy
  in People With Head and Neck Cancer\nEstimated primary completion: 20 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0472252
 3
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00781612-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT00781612)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Safety Extension Stud
 y of Trastuzumab Emtansine in Participants Previously Treated With Trastuz
 umab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in O
 ne of the Parent Studies\nEstimated primary completion: 30 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT00781612
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Multiple Targeted T
 herapies as Treatments for Participants With Non-Small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03505320-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03505320)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Stud
 y of Zolbetuximab (IMAB362) in Adults With Gastric Cancer\nEstimated prima
 ry completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03505320
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05184803-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05184803)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Phas
 e 2 Study of Neoadjuvant Docetaxel\, Oxaliplatin\, S-1 in Patients With Un
 resectable Locally Advanced or Distant Metastasis Limited to Lymph Node Ga
 stric Cancer\nEstimated primary completion: 30 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05184803
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04947189-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04947189)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: Seviteronel in Combin
 ation With Chemotherapy in Androgen-receptor Positive Metastatic Triple-ne
 gative Breast Cancer\nEstimated primary completion: 1 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04947189
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05189457-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05189457)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: First
  Strike\, Second Strike Therapies for High Risk Metastatic Castration Sens
 itive Prostate Cancer\nEstimated primary completion: 15 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05189457
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488222-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06488222)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Intravesical Gemcitabin
 e and Docetaxel for Low Grade Intermediate Risk Bladder Cancer\nEstimated 
 primary completion: August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06488222
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093931-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Taxotere (Docetaxel): Phase 4 readout est. (NCT07093931)
DESCRIPTION:Taxotere (Docetaxel)\, phase 4.\nStudy: Efficacy and Safety of 
 Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast
  Cancer\nEstimated primary completion: 1 August 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07093931
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925866-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07925866)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After
  Failure of First-Line Immunotherapy\nEstimated primary completion: 30 Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07925
 866
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05777278-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05777278)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildty
 pe NSCLC With MET Overexpression\nEstimated primary completion: 31 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05777278
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05818683-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05818683)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Prostate Cancer.\nStudy: A Stu
 dy of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metas
 tatic Prostate Cancer\nEstimated primary completion: 31 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05818683
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07306624-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07306624)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Ca
 ncer\nEstimated primary completion: 31 August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07306624
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05592626-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05592626)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of a Selective T Cell Receptor (TCR) Targeting\, Bifunctio
 nal Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid 
 Tumors\nEstimated primary completion: September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05592626
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776639-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07776639)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Iparomlimab and Tuvonra
 limab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Loca
 lly Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction\n
 Estimated primary completion: September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07776639
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04577014-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04577014)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: Retifanlimab (Anti-PD
 -1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft
  Tissue Sarcoma\nEstimated primary completion: 29 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04577014
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884282-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04884282)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second
 -line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After F
 irst-line Chemo-immunotherapy (Combi-TED)\nEstimated primary completion: 3
 0 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04884282
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05997615-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05997615)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Prostate Cancer.\nStudy: Safet
 y\, Pharmacokinetics\, and Preliminary Efficacy of VIR-5500 (AMX-500) in P
 rostate Cancer\nEstimated primary completion: 30 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05997615
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700420-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT07700420)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: Perioperative FLOT(D) W
 ith Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PUL
 SAR) in Esophageal Cancer\nEstimated primary completion: 1 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07700420
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02861573-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT02861573)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Study of Pembrolizumab (MK-3475) Combination 
 Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/
 KEYNOTE-365)\nEstimated primary completion: 22 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02861573
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266249-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04266249)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: CompassHER2-pCR: Decrea
 sing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and T
 argeted Therapy\nEstimated primary completion: 31 October 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04266249
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04615013-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT04615013)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: NBTXR3\, Chemotherapy\,
  and Radiation Therapy for the Treatment of Esophageal Cancer\nEstimated p
 rimary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04615013
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05494190-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Taxotere (Docetaxel): Phase na readout est. (NCT05494190)
DESCRIPTION:Taxotere (Docetaxel)\, phase na.\nStudy: The Management of Meta
 static Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma\nEstimate
 d primary completion: November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05494190
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663137-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06663137)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Study to Evaluate the
  Safety and Efficacy of NDV-01 in Participants With NMIBC\nEstimated prima
 ry completion: November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06663137
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059611-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07059611)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Neoadjuvant Intra-tumor
 al RP2 and FLOT in Gastroesophageal Adenocarcinoma\nEstimated primary comp
 letion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07059611
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220135-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07220135)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Trial of Neoadjuvant TH
 P vs TCHP for HER2-Amplified/Positive Breast Cancer\nEstimated primary com
 pletion: 14 November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07220135
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07225946)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Doc
 etaxel in Participants With Metastatic Castration-Resistant Prostate Cance
 r\nEstimated primary completion: 19 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123338-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06123338)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: A Stud
 y of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esopha
 gogastric Cancer\nEstimated primary completion: 30 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06123338
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-
 CD73 mAb\, Administered Alone and in Combination With a PD-1 Inhibitor or 
 Chemotherapy (the MORNINGSTAR Study)\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054312
 70
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05676931-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05676931)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Study With Various Immunotherapy Treatments in Participants With Lun
 g Cancer\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05676931
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520345-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06520345)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: The Study of 177Lu-TLX591 Plus SOC Versus SOC A
 lone in Patients With mCRPC (ProstACT Global)\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06520345
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07017673-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07017673)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Phase II Trial of Ivone
 scimab in Combination With Carboplatin + Docetaxel in Patients With Early-
 Stage Triple Negative Breast Cancer\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701767
 3
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358806-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT07358806)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: Study to Assess the Effect of OCT-598 in Patients With Advanced Soli
 d Tumors\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07358806
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503379-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07503379)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Evaluation of the Effic
 acy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in m
 HSPC\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07503379
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910827-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cet
 uximab +/- Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary 
 completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05910827
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516704-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT07516704)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Prostate Cancer.\nStudy: Safet
 y and Efficacy of Docetaxel\, Darolutamide\, and Homoharringtonine Combine
 d With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk 
 Prostate Cancer: A Multicenter Prospective\, Single-Arm Clinical Study\nEs
 timated primary completion: 1 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07516704
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Head and Neck Squamous Cell 
 Carcinoma.\nStudy: Testing the Use of Investigational Drugs Atezolizumab a
 nd/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line
  Treatment of Advanced-Stage Head and Neck Cancers\nEstimated primary comp
 letion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05063552
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669415-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07669415)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Study of LM-168 Combi
 ned With Other Anti-tumor Treatments in Participants With Advanced Solid T
 umors\nEstimated primary completion: 15 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07669415
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07102381)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Phase 2 Neoadjuvant S
 tudy of Zanidatamab in Combination With Chemotherapy in Participants With 
 HER2-positive Breast Cancer\nEstimated primary completion: 29 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07102381
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01154920-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT01154920)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Paclitaxel\, Carboplatin and Cetuximab (PCC) With Cetuxim
 ab\, Docetaxel\, Cisplatin and Fluorouracil (C-TPF) in Previously Untreate
 d Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01154920
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04840264-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04840264)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Doceta
 xel\, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bo
 wel Obstruction\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04840264
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05726370-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05726370)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Preoperative Pembrolizumab and Chemotherapy in Resectable
 \, Recurrent HNSCC\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05726370
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for Pe
 ople With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment W
 ith Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatmen
 t Trial)\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704191-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06704191)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: In-home Intravesical 
 Chemotherapy for the Treatment of Bladder Cancer\, INVITE Trial\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06704191
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732856-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06732856)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Gastric Cancer.\nStudy: A Ph
 ase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel\, Oxaliplatin a
 nd S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06732856
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214987-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07214987)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: PDT For Induction Therapy For Head And Neck Cancer\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07214987
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246317-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07246317)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Evaluation of Neoadjuva
 nt Therapy With Trastuzumab\, Pertuzumab\, Docetaxel\, and QL1706 in Early
  or Locally Advanced HER2+ Breast Cancer\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docet
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07246317
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402473-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07402473)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Optimize Neoadjuvant Th
 erapy in HER2-Positive Early-Stage Breast Cancer\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07402473
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528274-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07528274)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC
  After First-Line Immunotherapy Failure\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doceta
 xel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07528274
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618624-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07618624)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: BRIDGE Study: Neoadjuvant Finotonlimab\, Cetuximab\, and 
 Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07618624
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719479-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06719479)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3.\nStudy: A Clinical Trial to E
 valuate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(
 Note: It is Currently Phase II.).\nEstimated primary completion: 1 January
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06719479
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223568-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06223568)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or
  in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newl
 y Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer\nEstimated
  primary completion: 10 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06223568
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940180-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06940180)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Toripalimab With Chemotherapy for Sinus Cancer\nEstimated
  primary completion: 1 February 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06940180
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415031-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07415031)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Solid Tumor Study for
  Long Term Treatment of Cancer Patients Who Participated in Adagrasib Stud
 ies\nEstimated primary completion: 16 February 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07415031
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05027633-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05027633)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Immunotherapy With Chem
 otherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity /
  Paranasal Sinuses (I-NAPA)\nEstimated primary completion: 30 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05027633
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441890-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06441890)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: BRE-10: Biomarker Optim
 ization of Neoadjuvant Therapy in Breast Cancer\nEstimated primary complet
 ion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docet
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06441890
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805135-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07805135)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients 
 With Advanced Breast Cancer\nEstimated primary completion: 1 June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07805135
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05296798-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT05296798)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: A Study to Evaluate the
  Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzuma
 b\, Trastuzumab\, and Hyaluronidase-zzxf) Versus Phesgo in Participants Wi
 th Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)\n
 Estimated primary completion: 15 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05296798
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01935778-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT01935778)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Gastric Cancer.\nStudy: Compar
 e Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capeci
 tabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST
 15-08): TRIUMPH\nEstimated primary completion: 30 June 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT01935778
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04437329-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT04437329)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: Nedaplatin Versus Cispl
 atin in Treatment for Nasopharyngeal Carcinoma\nEstimated primary completi
 on: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04437329
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545955-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06545955)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: A Trial to Evaluate Int
 ravesical Nadofaragene Firadenovec Alone or in Combination With Chemothera
 py or Immunotherapy in Participants With High-grade BCG Unresponsive Non-m
 uscle Invasive Bladder Cancer\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06545955
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868732-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT06868732)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC\nEs
 timated primary completion: 30 June 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06868732
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797218-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07797218)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: Neoadjuvant Pyrotinib-t
 o-pertuzumab in HER2+ eBC\nEstimated primary completion: 30 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07797218
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204614-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT06204614)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: Drug Screening Using IM
 D in Bladder Cancer\nEstimated primary completion: 1 July 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06204614
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951646-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06951646)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced
  NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adapt
 ive)\nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06951646
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06145308)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Precision Treatment of 
 Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\n
 Estimated primary completion: 10 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06795503-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06795503)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: Non-Inferiority Study o
 n MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients\nEs
 timated primary completion: August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06795503
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102940-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07102940)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Efti in Patients With H
 ormone Receptor Positive/HER2-neg Breast Cancer\nEstimated primary complet
 ion: August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07102940
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05800587)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Dose Attenuated Chemotherapy in Compromised Patients With Lung Cance
 r\nEstimated primary completion: 1 August 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645846-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07645846)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Neoadjuvant Docetaxel\,
  Cisplatin\, and Dual Immunotherapy for Sinonasal Carcinoma\nEstimated pri
 mary completion: 1 August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07645846
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900516-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07900516)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Prospective\, Phase I
 I\, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerc
 iclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Canc
 er.\nEstimated primary completion: 1 August 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07900516
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947823-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07947823)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: ASTAR: Sacituzumab Govi
 tecan For Breast Cancer\nEstimated primary completion: 1 September 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07947823
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841055-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06841055)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Safety and Preliminary Efficacy of Pumitamig (BNT327)\, an Investiga
 tional Therapy for Patients With Non-small Cell Lung Cancer in Combination
  With Chemotherapy as First-line or Second-line Treatment\nEstimated prima
 ry completion: October 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06841055
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609251-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07609251)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Clinical Study of SCTB41 Combined With Docetaxel in Patients With 
 Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Canc
 er（Phase II Study Ongoing）\nEstimated primary completion: October 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07609251
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547592-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07547592)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Gemcitabine and Docetax
 el With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma\nEstimate
 d primary completion: 30 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07547592
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682780-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281225
DTEND;VALUE=DATE:20281226
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06682780)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: A Phase I/II Study of
  LM-2417 in Subjects With Advanced Solid Tumours\nEstimated primary comple
 tion: 25 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06682780
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03317158-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT03317158)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: Modern Immunotherapy 
 in BCG-Unresponsive\, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Inv
 asive Urothelial Carcinoma of the Bladder\nEstimated primary completion: 3
 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doce
 taxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03317158
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382559-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05382559)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: A Study of ASP3082 in A
 dults With Advanced Solid Tumors\nEstimated primary completion: 31 Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0538255
 9
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730580-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07730580)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Study
  of XNW5004 Tablets in Advanced Prostate Cancer\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07730580
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734130-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06734130)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Adapt
 ive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive 
 Prostate Cancer\nEstimated primary completion: January 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06734130
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: Beamion BCGC-1: A Stu
 dy to Find a Suitable Dose of Zongertinib Used Alone and in Combination Wi
 th Other Treatments to Test Whether it Helps People With Different Types o
 f HER2+ Cancer That Has Spread\nEstimated primary completion: 8 January 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06324357
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353386-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06353386)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Substudy 01A: Safety and Efficacy of Opevesos
 tat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Partici
 pants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-568
 4-01A)\nEstimated primary completion: 15 January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06353386
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279130-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06279130)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3.\nStudy: Pan-tumor Neoadjuvant
  Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology C
 ombinations\nEstimated primary completion: 29 January 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06279130
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: SYS6090 Combination Therapy in Advanced Lung Cancer\nEstimated pri
 mary completion: 28 February 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07472647
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06266299-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT06266299)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of KK2269 in Adult Participants With Solid Tumors\nEstimated
  primary completion: March 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06266299
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03493425-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03493425)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Chemotherapy Before Sur
 gery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treat
 ing Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by 
 Surgery\nEstimated primary completion: 31 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03493425
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625930-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07625930)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: RESTAGE (REpurposing ST
 Atins to Improve Outcomes in GastroEsophageal Cancer) Trial\nEstimated pri
 mary completion: April 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07625930
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699757-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT07699757)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion\nE
 stimated primary completion: April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07699757
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06632327)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: Comparing Impact of Treatment Before or After Surgery in Patients Wi
 th Stage II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary 
 completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06632327
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06241456-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT06241456)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: FT825/ONO-8250\, an Off
 -the-Shelf\, HER2 CAR-T\, With or Without Monoclonal Antibodies in Advance
 d Solid Tumors\nEstimated primary completion: 1 May 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06241456
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527806-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07527806)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Optimization of Dynamic
  Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on H
 ER2-PET/CT Molecular Imaging\nEstimated primary completion: 1 May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07527806
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06078709-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290525
DTEND;VALUE=DATE:20290526
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06078709)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Preoperative Hypofracti
 onated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junctio
 n Adenocarcinoma\nEstimated primary completion: 25 May 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06078709
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05901428-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT05901428)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: TCb vs EC-T in High Ris
 k ER+/HER2- Breast Cancer\nEstimated primary completion: June 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05901428
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06291064-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06291064)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Trial Studying Chemothe
 rapy in Nigerian Women With Triple Negative Breast Cancer\nEstimated prima
 ry completion: June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06291064
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07907653-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07907653)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Deute
 nzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Be
 fore Surgery for High-Risk Localized or Locally Advanced Prostate Cancer\n
 Estimated primary completion: July 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07907653
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07698535-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290705
DTEND;VALUE=DATE:20290706
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07698535)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Metastatic Castration-Resistan
 t Prostate Cancer.\nStudy: Measuring Circulating Tumor Deoxyribonucleic Ac
 id Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation 
 in Patients With Metastatic Castration-Resistant Prostate Cancer\, DYNAMO 
 Trial\nEstimated primary completion: 5 July 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07698535
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03228667)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: QUILT-3.055: A Study of Combination Immunotherapies in Patients Who 
 Have Previously Received Treatment With Immune Checkpoint Inhibitors\nEsti
 mated primary completion: 31 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828873-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07828873)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: A Single-Arm Study of Q
 L1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastri
 c/GEJ Adenocarcinoma\nEstimated primary completion: September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07828873
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05541016-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290906
DTEND;VALUE=DATE:20290907
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05541016)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: De-Escalated Adjuvant a
 nd Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA\nEstimated 
 primary completion: 6 September 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05541016
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05538663-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT05538663)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: Intravesical BCG vs GEM
 DOCE in NMIBC\nEstimated primary completion: 1 November 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05538663
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464145-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07464145)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: A Study of NDV-01 (Sust
 ained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invas
 ive Bladder Cancer\nEstimated primary completion: December 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07464145
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06724042-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT06724042)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: Study of ISM5939 in Pat
 ients With Advanced and/or Metastatic Solid Tumors\nEstimated primary comp
 letion: 30 December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06724042
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747740-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07747740)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Sequential Gemcitabine 
 Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive No
 n-Muscle-Invasive Bladder Cancer\nEstimated primary completion: 30 Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0774774
 0
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972615-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06972615)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Intravesical Chemothera
 py in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exp
 osed to BCG Therapy\nEstimated primary completion: 31 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06972615
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354984-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07354984)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: A Single-Arm Phase II Clinical Study of Docetaxel Combine
 d With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for 
 Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated prim
 ary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07354984
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850973-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07850973)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2.\nStudy: Phase 1/2 Study Of PA
 RP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemother
 apy In Refractory And Relapsed Germ Cell Tumors\nEstimated primary complet
 ion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07850973
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142189-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05142189)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: Clinical Trial Evaluating the Safety\, Tolerability and Preliminary 
 Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non
 -small Cell Lung Cancer\nEstimated primary completion: February 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05142189
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06439693)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: The SAPPHO Study: Seque
 ntial Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Canc
 er\nEstimated primary completion: 30 March 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06439693
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07333066-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT07333066)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: Phase
  III Randomized International Open Label Clinical Trial of Treatment Inten
 sification With Docetaxel Plus Apalutamide in Patients With Metastatic Hor
 mone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response Aft
 er Initial Treatment With Apalutamide: REINFORCE Trial.\nEstimated primary
  completion: 31 March 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07333066
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872722-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07872722)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Gastric Cancer.\nStudy: Zolbet
 uximab\, Durvalumab\, and FLOT Combination Neoadjuvant Chemotherapy for CL
 DN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
 \nEstimated primary completion: 31 March 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07872722
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05719558-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05719558)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: A Study of ASP1002 in A
 dults for Treatment of Solid Tumors\nEstimated primary completion: 30 Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0571955
 8
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018570-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07018570)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: An Open Label Phase 2 S
 tudy of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizu
 mab and Short Radiation for Patients With Locally Advanced Gastroesophagea
 l Junction Adenocarcinoma\nEstimated primary completion: June 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07018570
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282588-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06282588)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Prostate Cancer.\nStudy: Tre
 atment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and 
 Molecular Tracers\nEstimated primary completion: 31 July 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06282588
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05954312-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05954312)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1.\nStudy: A First-in-Human (FIH) 
 Study to Evaluate the Safety and Tolerability of VVD-130037 in Participant
 s With Advanced Solid Tumors\nEstimated primary completion: 31 August 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05954312
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227065-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06227065)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Precise Chemoresection 
 in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids\nEstima
 ted primary completion: 30 November 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06227065
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05919537-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Taxotere (Docetaxel): Phase 1 readout est. (NCT05919537)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: Study of an Anti-HER3 Antibody\, HMBD-001\, With or Without Chemothe
 rapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutati
 on\nEstimated primary completion: 1 March 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05919537
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592924-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20310314
DTEND;VALUE=DATE:20310315
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06592924)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: Docet
 axel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic C
 astration Sensitive Prostate Cancer and Suboptimal PSA Response\nEstimated
  primary completion: 14 March 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06592924
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06320067-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06320067)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: A Ran
 domised Controlled Platform Trial Testing Treatments in Metastatic Hormone
  Sensitive Prostate Cancer\nEstimated primary completion: April 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06320067
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05883852-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT05883852)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: EC-THP Versus TCbHP in 
 HER2-positive Lymph Node Positive Early Breast Cancer\nEstimated primary c
 ompletion: 1 July 2031. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05883852
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of BMS-986340 as Monotherapy and as Combination Therapy in
  Participants With Advanced Solid Tumors\nEstimated primary completion: 31
  August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetax
 el#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4895709
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06042569-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20310920
DTEND;VALUE=DATE:20310921
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06042569)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Dose-Reduced Docetaxel 
 With Cyclophosphamide for the Treatment of Vulnerable Older Women With Sta
 ge I-III HER2 Negative Breast Cancer\, the DOROTHY Trial\nEstimated primar
 y completion: 20 September 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06042569
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931340-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20311111
DTEND;VALUE=DATE:20311112
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06931340)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Prostate Cancer.\nStudy: Testi
 ng the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormon
 al Therapy and Apalutamide) for Metastatic Prostate Cancer\, ASPIRE Trial\
 nEstimated primary completion: 11 November 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06931340
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02128906-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20311216
DTEND;VALUE=DATE:20311217
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT02128906)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Radiotherapy With Cispl
 atin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Inte
 raction Design\nEstimated primary completion: 16 December 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT02128906
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730151-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07730151)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: Effic
 acy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuv
 ant Therapy for Locally Advanced Prostate Cancer.\nEstimated primary compl
 etion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07730151
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952504-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20320524
DTEND;VALUE=DATE:20320525
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06952504)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: A Study to Compare Saci
 tuzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) 
 Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repa
 ir Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-e
 n29)\nEstimated primary completion: 24 May 2032. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06952504
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645326-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07645326)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Prostate Cancer.\nStudy: RISK-
 ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)\nEs
 timated primary completion: August 2032. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07645326
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743632-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07743632)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Neoadjuvant Angiogenesi
 s-Targeting Bispecific Chemoimmunotherapy for TNBC\nEstimated primary comp
 letion: December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07743632
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322263-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20330101
DTEND;VALUE=DATE:20330102
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07322263)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Intravesical GEM/DOCE f
 or HR BCG-Unresponsive NMIBC\nEstimated primary completion: 1 January 2033
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07322263
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929768-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT05929768)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3.\nStudy: Shorter Chemo-Immunothe
 rapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Ca
 ncer\nEstimated primary completion: 31 March 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05929768
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06348134)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2.\nStudy: Assessing the Efficacy 
 and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer
  Before and After Surgery\nEstimated primary completion: 1 July 2034. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06348134
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667400-9029@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20361001
DTEND;VALUE=DATE:20361002
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07667400)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Docetaxel and SX-682 in Recurrent/Metastatic 
 Head and Neck Squamous Cell Carcinoma\, Salivary Gland Carcinoma\, and Adv
 anced Prostate Cancer\nEstimated primary completion: 1 October 2036. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07667400
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
